Paragraphs
PROVEN PERFORMANCE ACROSS THREE PIVOTAL STUDIES
The PRECISE and PRECISE II trials investigated the system’s accuracy, longevity and safety, along with glycemic control data and self-reported quality of life. The PRECISION study captured additional data on safety and accuracy. Combined, the three studies supported the clinical efficacy of Eversense and its exceptional long-term accuracy and wear time.
Selector Id
evidence-block-one
Selector Class
evidence-block-one
The PRECISE (European) Trial
Performed over 180 days at 7 clinical sites in Europe, it studied a group of 71 adults with Type 1 and Type 2 diabetes using the Eversense CGM System at home and in the clinic...
Selector Id
evidence-block-two
Selector Class
evidence-block-two
The PRECISE II (U.S.) Trial
The second study (PRECISE II), performed in the United States, investigated the efficacy and safety of the Eversense CGM System during 90 days of continuous sensor wear...
Selector Id
evidence-block-three
Selector Class
evidence-block-three
The PRECISION Trial
This trial was designed to provide additional data on the Eversense CGM system across three metrics...
Selector Id
evidence-block-four
Selector Class
evidence-block-four
Selector Id
product-sheet-evidence
Selector Class
Product-sheet
Sub Description
The advanced sensor technology and under-the-skin placement help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.